Abstract
For the immune system to mount an effective antitumor T-cell response, an adequate number of T-cells specific for the antigens expressed by the malignancy must be activated [1]. Since most antigens expressed by tumors are "self"- antigens, tumor antigens often lack endogenous immunogenicity and thus do not sufficiently activate T-cells to levels that can mediate tumor eradication. In addition, virtually all solid tumor cells lack the costimulatory molecules necessary to activate tumor-specific T-cells. Approaches that stimulate immune responses to these tumor antigens have the potential to alter this poor responsiveness. This theory has promoted the use of active immunotherapy to generate immune responses against tumor-associated antigens (TAAs) for the treatment of cancer. As one such vaccine strategy, we have utilized poxviruses as delivery vehicles for TAAs in combination with T-cell costimulatory molecules. Initial studies have demonstrated that the insertion of costimulatory molecule trangenes into viral vectors, along with a TAA transgene, greatly enhances the immune response to the antigen. Using this approach, a TRIad of COstimulatory Molecules (TRICOM; B7-1, ICAM-1 and LFA-3) has been shown to enhance T-cell responses to TAAs to levels far greater than any one or two of the costimulatory molecules in combination. In this article, preclinical findings and recent clinical applications of TRICOMbased vaccines as a cancer immunotherapy are reviewed.
Keywords: TRICOM, costimulation, vaccination, TAA, cancer immunotherapy
Current Pharmaceutical Design
Title: TRICOM Vector Based Cancer Vaccines
Volume: 12 Issue: 3
Author(s): Charlie T. Garnett, John W. Greiner, Kwong-Yok Tsang, Chie Kudo-Saito, Douglas W. Grosenbach, Mala Chakraborty, James L. Gulley, Philip M. Arlen, Jeffrey Schlom and James W. Hodge
Affiliation:
Keywords: TRICOM, costimulation, vaccination, TAA, cancer immunotherapy
Abstract: For the immune system to mount an effective antitumor T-cell response, an adequate number of T-cells specific for the antigens expressed by the malignancy must be activated [1]. Since most antigens expressed by tumors are "self"- antigens, tumor antigens often lack endogenous immunogenicity and thus do not sufficiently activate T-cells to levels that can mediate tumor eradication. In addition, virtually all solid tumor cells lack the costimulatory molecules necessary to activate tumor-specific T-cells. Approaches that stimulate immune responses to these tumor antigens have the potential to alter this poor responsiveness. This theory has promoted the use of active immunotherapy to generate immune responses against tumor-associated antigens (TAAs) for the treatment of cancer. As one such vaccine strategy, we have utilized poxviruses as delivery vehicles for TAAs in combination with T-cell costimulatory molecules. Initial studies have demonstrated that the insertion of costimulatory molecule trangenes into viral vectors, along with a TAA transgene, greatly enhances the immune response to the antigen. Using this approach, a TRIad of COstimulatory Molecules (TRICOM; B7-1, ICAM-1 and LFA-3) has been shown to enhance T-cell responses to TAAs to levels far greater than any one or two of the costimulatory molecules in combination. In this article, preclinical findings and recent clinical applications of TRICOMbased vaccines as a cancer immunotherapy are reviewed.
Export Options
About this article
Cite this article as:
Garnett T. Charlie, Greiner W. John, Tsang Kwong-Yok, Kudo-Saito Chie, Grosenbach W. Douglas, Chakraborty Mala, Gulley L. James, Arlen M. Philip, Schlom Jeffrey and Hodge W. James, TRICOM Vector Based Cancer Vaccines, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201929
DOI https://dx.doi.org/10.2174/138161206775201929 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Current Drug Safety The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story
Current Medicinal Chemistry - Anti-Cancer Agents Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Cancer-Homing Toxins
Current Pharmaceutical Design Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions
Letters in Organic Chemistry Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Relevance of Drug Metabolizing Enzyme Activity Modulation by Tea Polyphenols in the Inhibition of Esophageal Tumorigenesis
Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Recent Advances in Delivery of Cytokines, Growth Factors, and Molecules of Therapeutic Interest from Hyaluronan-based Hydrogels
Current Tissue Engineering (Discontinued) Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry